STOCKHOLM, November 15, 2017 /PRNewswire/ --
Oncoinvent announced today that European Patent 3111959 entitled "Radiotherapeutic particles and suspensions" has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer. This patent provides patent protection for the company's lead product candidate Radspherin® in Europe.
The company further announced that US Patent 9,782,500 entitled "Monoclonal Antibody and Derivatives" has issued. The patent relates to a novel anti-CD146 antibody and derivatives that can be used for therapy and imaging, diagnosis and immunostaining. CD146 is an antigen that is up-regulated in numerous cancers including melanoma, prostate cancer, breast cancer and lung cancer.
Jan A. Alfheim, Oncoinvent's CEO commented: "This is significant milestone in both the development of our lead product candidate, Radspherin® as well as development of our pipeline of follow on product candidates behind Radspherin®. With the Radspherin® patent issuing in Europe we have secured protection of Radspherin® until 2035 in most of the major future markets for the product." Alfheim continued, "The issuance of our OI-3 antibody patent in the USA provides Oncoinvent a patent protection of novel OI-3 cancer immunotherapies, as well as a radioimmunotherapies based on a combination our Ra-224 radioisotope technology platform and the OI-3 antibody."
For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Ole Peter Nordby, Chief Financial Officer
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Oncoinvent AS